AMERICAN SOCIETY OF HEMATOLOGY Annual Report. Over the course of a challenging year, ASH continued its meaningful work in advancing the field of hematology, supporting those whose training and research were disrupted by the pandemic, providing tools to help hematologists navigate patient care, and addressing issues of diversity, equity, and inclusion across the

medical field.

BLOOD HERISHANU COVID VACCINE AND CLL Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is a journal of the American Society of Hematology (ASH) (www.hematology.org).. Contact: Leah Enser, American Society of Hematology lenser@hematology.org; 202-552-4927

COVID-19 AND CML

At this time, based on best available information, patients with chronic myeloid leukemia (CML) are considered appropriate to receive vaccines against COVID-19. While rare special circumstances may exist, most patients, whether early in treatment, in ongoing response, in deep remission, or off therapy having pursued ‘treatment free

remission

COVID-19 AND CLL

Phone 202-776-0544 Toll Free 866-828-1231 Fax 202-776-0545 ASH CLINICAL PRACTICE GUIDELINES ASH Clinical Practice Guidelines. ASH Guidelines are developed by leading clinical, methodological, and patient experts through a rigorous process to review evidence and write actionable recommendations. Our state-of-the-art methodology ensures that they meet the highest standards for trustworthiness and transparency. Guideline panels are

COVID-19 AND ITP

Severe COVID-19 infection is accompanied by a risk of thrombosis, but there is no evidence that this risk is increased by raising platelet counts to hemostatic levels or exacerbated by any specific form of ITP management, even splenectomy and thrombopoietic (TPO) agents which may be associated with some excess thrombosis in non-COVID ITP settings. HEMATOLOGY REVIEW SERIES The ASH Hematology Review Series is designed for fellows preparing to take the internal medicine hematology certification exam or those desiring a comprehensive update of hematology standards of care. This series provides a free review of hematology patterned after the American Board of Internal Medicine (ABIM) Certification Examination

Blueprint.

THROMBOSIS WITH THROMBOCYTOPENIA SYNDROME Shortness of breath. Leg pain or swelling. Petechiae, easy bruising, or bleeding. If TTS is suspected, perform immediate CBC with platelet count and imaging for thrombosis based on symptoms. If thrombocytopenia or thrombosis are present, recommend urgent consultation from hematologist with expertise in hemostasis. COVID-19 AND PULMONARY EMBOLISM An elevated D-dimer level does not confirm a diagnosis of PE/DVT in a patient with COVID-19 because the elevated D-dimer may result from the COVID-19 infection or other causes. If possible, CTPA and/or bilateral CUS should be performed to investigate for PE/DVT. It is important to determine if there are any new clinical findings that indicate DIAGNOSIS AND MANAGEMENT OF SUSPECTED VACCINE-INDUCED Austria/Germany Norway UK Number of patients 11 5 23 Onset post vaccine, days 5-16 7-10 6-24 Age, years 22-49 32-54 21-77 Sex: male 2

1 9 female 9 4 14

AMERICAN SOCIETY OF HEMATOLOGY Annual Report. Over the course of a challenging year, ASH continued its meaningful work in advancing the field of hematology, supporting those whose training and research were disrupted by the pandemic, providing tools to help hematologists navigate patient care, and addressing issues of diversity, equity, and inclusion across the

medical field.

BLOOD HERISHANU COVID VACCINE AND CLL Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is a journal of the American Society of Hematology (ASH) (www.hematology.org).. Contact: Leah Enser, American Society of Hematology lenser@hematology.org; 202-552-4927

COVID-19 AND CML

At this time, based on best available information, patients with chronic myeloid leukemia (CML) are considered appropriate to receive vaccines against COVID-19. While rare special circumstances may exist, most patients, whether early in treatment, in ongoing response, in deep remission, or off therapy having pursued ‘treatment free

remission

COVID-19 AND CLL

Phone 202-776-0544 Toll Free 866-828-1231 Fax 202-776-0545 ASH CLINICAL PRACTICE GUIDELINES ASH Clinical Practice Guidelines. ASH Guidelines are developed by leading clinical, methodological, and patient experts through a rigorous process to review evidence and write actionable recommendations. Our state-of-the-art methodology ensures that they meet the highest standards for trustworthiness and transparency. Guideline panels are

COVID-19 AND ITP

Severe COVID-19 infection is accompanied by a risk of thrombosis, but there is no evidence that this risk is increased by raising platelet counts to hemostatic levels or exacerbated by any specific form of ITP management, even splenectomy and thrombopoietic (TPO) agents which may be associated with some excess thrombosis in non-COVID ITP settings. HEMATOLOGY REVIEW SERIES The ASH Hematology Review Series is designed for fellows preparing to take the internal medicine hematology certification exam or those desiring a comprehensive update of hematology standards of care. This series provides a free review of hematology patterned after the American Board of Internal Medicine (ABIM) Certification Examination

Blueprint.

THROMBOSIS WITH THROMBOCYTOPENIA SYNDROME Shortness of breath. Leg pain or swelling. Petechiae, easy bruising, or bleeding. If TTS is suspected, perform immediate CBC with platelet count and imaging for thrombosis based on symptoms. If thrombocytopenia or thrombosis are present, recommend urgent consultation from hematologist with expertise in hemostasis. COVID-19 AND PULMONARY EMBOLISM An elevated D-dimer level does not confirm a diagnosis of PE/DVT in a patient with COVID-19 because the elevated D-dimer may result from the COVID-19 infection or other causes. If possible, CTPA and/or bilateral CUS should be performed to investigate for PE/DVT. It is important to determine if there are any new clinical findings that indicate DIAGNOSIS AND MANAGEMENT OF SUSPECTED VACCINE-INDUCED Austria/Germany Norway UK Number of patients 11 5 23 Onset post vaccine, days 5-16 7-10 6-24 Age, years 22-49 32-54 21-77 Sex: male 2

1 9 female 9 4 14

ASH CLINICAL PRACTICE GUIDELINES ASH Clinical Practice Guidelines. ASH Guidelines are developed by leading clinical, methodological, and patient experts through a rigorous process to review evidence and write actionable recommendations. Our state-of-the-art methodology ensures that they meet the highest standards for trustworthiness and transparency. Guideline panels are

ASH MEMBERSHIP

ASH Membership. Join a diverse community of more than 18,000 hematologists who are working to conquer blood diseases worldwide. Whether you are a medical student planning your career in hematology or an established physician or scientist with years of experience in the field, ASH offers benefits and opportunities for hematologists

around the

COVID-19 AND PULMONARY EMBOLISM An elevated D-dimer level does not confirm a diagnosis of PE/DVT in a patient with COVID-19 because the elevated D-dimer may result from the COVID-19 infection or other causes. If possible, CTPA and/or bilateral CUS should be performed to investigate for PE/DVT. It is important to determine if there are any new clinical findings that indicate ASH-ASTCT COVID-19 AND VACCINES: FREQUENTLY ASKED The BNT162b2 (Pfizer/BioNTech) and the mRNA-1273 (Moderna) COVID-19 vaccines have both been shown in large phase III clinical trials to be more than 90 percent effective at preventing lab-confirmed COVID-19 illness and severe infections. 1,2 The single-dose recombinant, replication-incompetent adenovirus serotype 26 vector-based vaccine

(Ad26

COVID-19 AND COAGULOPATHY The most common pattern of coagulopathy observed in patients hospitalized with COVID-19 is characterized by elevations in fibrinogen and D-dimer levels, and mild prolongation of PT/aPTT. This correlates with a parallel rise in markers of inflammation (e.g. CRP). Unlike the pattern seen in classic DIC from bacterial sepsis or trauma COVID-19 AND MYELOPROLIFERATIVE NEOPLASMS The risks of bleeding on anticoagulation are higher in MPN patients, particularly in those with prior hemorrhages or extreme thrombocytosis or thrombocytopenia. The risk is even higher in MPN patients with hepatic failure (INR >1.5) or severe renal failure (filtration rate < 30ml/min per m2). We strongly recommend that COVID-19 infected and COVID-19 AND D-DIMER Although it is not clear what effect anticoagulation has on D-dimer levels in the setting of COVID-19, very low D-dimer levels are usually observed in patients receiving anticoagulation. Because D-dimer is a product of cross-linked fibrin, it is considered a sensitive biomarker to rule out venous thromboembolism. COVID-19 AND INDOLENT LYMPHOMAS According to one report, the more intensive the therapy, the greater the impact on clinical outcomes from COVID-19. Furthermore, patients with lymphoma may have an increased susceptibility to infection with SARS-CoV-2. Patients should be encouraged to be vaccinated for the flu and cautioned to follow recommendations for reducing risks of POSTER WALKS GUIDELINES AND APPLICATION Phone 202-776-0544 Toll Free 866-828-1231 Fax 202-776-0545 ASH VTE GUIDELINES: PREGNANCY ASH VTE Guidelines: Pregnancy. Pregnancy-associated VTE is a leading cause of maternal morbidity and mortality. The diagnosis, prevention, and treatment of pregnancy-associated VTE are particularly difficult because of the need to consider fetal, as well as maternal, well-being. These guidelines address these challenging issues. BLOOD HERISHANU COVID VACCINE AND CLL Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is a journal of the American Society of Hematology (ASH) (www.hematology.org).. Contact: Leah Enser, American Society of Hematology lenser@hematology.org; 202-552-4927

COVID-19 AND CML

At this time, based on best available information, patients with chronic myeloid leukemia (CML) are considered appropriate to receive vaccines against COVID-19. While rare special circumstances may exist, most patients, whether early in treatment, in ongoing response, in deep remission, or off therapy having pursued ‘treatment free

remission

COVID-19 AND MYELODYSPLASTIC SYNDROMES There are no data indicating that patients with MDS are more likely to contract COVID-19 than patients with healthy bone marrows. Studies from Italy, the US, UK, and China indicate a higher mortality rate from COVID-19 among patients with a history of cancer, including hematological malignancy, compared to those without such a history.

COVID-19 AND CLL

Phone 202-776-0544 Toll Free 866-828-1231 Fax 202-776-0545 COVID-19 AND MULTIPLE MYELOMA Multiple myeloma patients with active disease need treatment to avoid morbidity and mortality, despite the COVID-19 pandemic; however, treatment can be individualized to limit additional exposure to COVID-19. For example, we recommend starting triplet therapy with bortezomib, lenalidomide and dexamethasone (RVD) for 6- 12 cycles

followed by

COVID-19 AND ITP

Severe COVID-19 infection is accompanied by a risk of thrombosis, but there is no evidence that this risk is increased by raising platelet counts to hemostatic levels or exacerbated by any specific form of ITP management, even splenectomy and thrombopoietic (TPO) agents which may be associated with some excess thrombosis in non-COVID ITP settings. HEMATOLOGY REVIEW SERIES The ASH Hematology Review Series is designed for fellows preparing to take the internal medicine hematology certification exam or those desiring a comprehensive update of hematology standards of care. This series provides a free review of hematology patterned after the American Board of Internal Medicine (ABIM) Certification Examination

Blueprint.

COVID-19 AND PULMONARY EMBOLISM An elevated D-dimer level does not confirm a diagnosis of PE/DVT in a patient with COVID-19 because the elevated D-dimer may result from the COVID-19 infection or other causes. If possible, CTPA and/or bilateral CUS should be performed to investigate for PE/DVT. It is important to determine if there are any new clinical findings that indicate COVID-19 AND THALASSEMIA Luspatercept has been approved for adults with transfusion dependent beta thalassemia and has been shown to significantly reduce transfusion burden in this population. No data are available to date on luspatercept and COVID-19. If patients are currently taking luspatercept, there are no theoretical reasons to stop treatment. DIAGNOSIS AND MANAGEMENT OF SUSPECTED VACCINE-INDUCED Austria/Germany Norway UK Number of patients 11 5 23 Onset post vaccine, days 5-16 7-10 6-24 Age, years 22-49 32-54 21-77 Sex: male 2

1 9 female 9 4 14

BLOOD HERISHANU COVID VACCINE AND CLL Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is a journal of the American Society of Hematology (ASH) (www.hematology.org).. Contact: Leah Enser, American Society of Hematology lenser@hematology.org; 202-552-4927

COVID-19 AND CML

At this time, based on best available information, patients with chronic myeloid leukemia (CML) are considered appropriate to receive vaccines against COVID-19. While rare special circumstances may exist, most patients, whether early in treatment, in ongoing response, in deep remission, or off therapy having pursued ‘treatment free

remission

COVID-19 AND MYELODYSPLASTIC SYNDROMES There are no data indicating that patients with MDS are more likely to contract COVID-19 than patients with healthy bone marrows. Studies from Italy, the US, UK, and China indicate a higher mortality rate from COVID-19 among patients with a history of cancer, including hematological malignancy, compared to those without such a history.

COVID-19 AND CLL

Phone 202-776-0544 Toll Free 866-828-1231 Fax 202-776-0545 COVID-19 AND MULTIPLE MYELOMA Multiple myeloma patients with active disease need treatment to avoid morbidity and mortality, despite the COVID-19 pandemic; however, treatment can be individualized to limit additional exposure to COVID-19. For example, we recommend starting triplet therapy with bortezomib, lenalidomide and dexamethasone (RVD) for 6- 12 cycles

followed by

COVID-19 AND ITP

Severe COVID-19 infection is accompanied by a risk of thrombosis, but there is no evidence that this risk is increased by raising platelet counts to hemostatic levels or exacerbated by any specific form of ITP management, even splenectomy and thrombopoietic (TPO) agents which may be associated with some excess thrombosis in non-COVID ITP settings. HEMATOLOGY REVIEW SERIES The ASH Hematology Review Series is designed for fellows preparing to take the internal medicine hematology certification exam or those desiring a comprehensive update of hematology standards of care. This series provides a free review of hematology patterned after the American Board of Internal Medicine (ABIM) Certification Examination

Blueprint.

COVID-19 AND PULMONARY EMBOLISM An elevated D-dimer level does not confirm a diagnosis of PE/DVT in a patient with COVID-19 because the elevated D-dimer may result from the COVID-19 infection or other causes. If possible, CTPA and/or bilateral CUS should be performed to investigate for PE/DVT. It is important to determine if there are any new clinical findings that indicate COVID-19 AND THALASSEMIA Luspatercept has been approved for adults with transfusion dependent beta thalassemia and has been shown to significantly reduce transfusion burden in this population. No data are available to date on luspatercept and COVID-19. If patients are currently taking luspatercept, there are no theoretical reasons to stop treatment. DIAGNOSIS AND MANAGEMENT OF SUSPECTED VACCINE-INDUCED Austria/Germany Norway UK Number of patients 11 5 23 Onset post vaccine, days 5-16 7-10 6-24 Age, years 22-49 32-54 21-77 Sex: male 2

1 9 female 9 4 14

THROMBOSIS WITH THROMBOCYTOPENIA SYNDROME Shortness of breath. Leg pain or swelling. Petechiae, easy bruising, or bleeding. If TTS is suspected, perform immediate CBC with platelet count and imaging for thrombosis based on symptoms. If thrombocytopenia or thrombosis are present, recommend urgent consultation from hematologist with expertise in hemostasis. COVID-19 AND MYELOPROLIFERATIVE NEOPLASMS The risks of bleeding on anticoagulation are higher in MPN patients, particularly in those with prior hemorrhages or extreme thrombocytosis or thrombocytopenia. The risk is even higher in MPN patients with hepatic failure (INR >1.5) or severe renal failure (filtration rate < 30ml/min per m2). We strongly recommend that COVID-19 infected and

COVID-19 AND TTP

Patients with cTTP that become infected with COVID-19 similarly would be at increased risk for an acute TTP episode as a result of the infection and the secondary inflammatory state. Patients with cTTP and COVID-19 infection should be monitored carefully for hemolysis. cTTP patients with COVID-19 may need an intensified plasma infusion

schedule

COVID-19 AND HODGKIN LYMPHOMA The COVID-19 PANDEMIC: A Rapid Global response for Children with Cancer from SIOP, COG, SIOP-E, SIOP-PODC, IPSO, PROS, CCI and St Jude Global. Authorea. April 25, 2020. DOI: 10.22541/au.158777298.87289192. Clift, Coupland CAC, Keogh RH et al. Living risk prediction algorithm (QCOVIDk) for risk of hospital admission and mortality from COVID-19 AND THALASSEMIA Luspatercept has been approved for adults with transfusion dependent beta thalassemia and has been shown to significantly reduce transfusion burden in this population. No data are available to date on luspatercept and COVID-19. If patients are currently taking luspatercept, there are no theoretical reasons to stop treatment. COVID-19 AND INDOLENT LYMPHOMAS According to one report, the more intensive the therapy, the greater the impact on clinical outcomes from COVID-19. Furthermore, patients with lymphoma may have an increased susceptibility to infection with SARS-CoV-2. Patients should be encouraged to be vaccinated for the flu and cautioned to follow recommendations for reducing risks of LEGENDS IN HEMATOLOGY Legends in Hematology. Many hematologists have been instrumental in the development of ASH and have greatly advanced the field through their numerous contributions. Meet some of these notable leaders profiled as part of ASH's 50th anniversary in 2008 by following the links below to read their profiles and hear their insights about the

field and

ASH VITT MEDIA ADVISORY The American Society of Hematology (ASH) (www.hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 60 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, DIAGNOSIS AND MANAGEMENT OF SUSPECTED VACCINE-INDUCED Austria/Germany Norway UK Number of patients 11 5 23 Onset post vaccine, days 5-16 7-10 6-24 Age, years 22-49 32-54 21-77 Sex: male 2

1 9 female 9 4 14

PEDIATRIC TO ADULT HEMATOLOGIC CARE TRANSITION Recognizing the need to improve this transition process and to enhance care coordination between practices, the American Society of Hematology (ASH) has developed the following pediatric-to-adult transition toolkit. The toolkit provides both an assessment and summary form that are designed to facilitate conversations between

patients, parents

Jump to Main Content

* About ASH

* ASH Foundation

*

__ Log in or create an account

*

Submit __ __

*

* Research

* Education

* Advocacy

* Careers

* Meetings

* Publications

* Awards

* Newsroom

* About ASH

* ASH Foundation

* My Account

* Membership

* Global Initiatives Helping hematologists conquer blood diseases worldwide

* Research

* Education

* Advocacy

* Careers

* Meetings

* Publications

* Awards

* Newsroom

COVID-19 RESOURCES FOR HEMATOLOGISTS The novel (new) coronavirus is having an impact on medicine and hematology around the globe. To help keep you informed, ASH has created a collection of resources for hematologists. VIEW COVID-19 RESOURCES

LANDING PAGE

__

LATEST UPDATES

NEW ASH CLINICAL PRACTICE GUIDELINES CLINICAL TRIAL SUPPORT CENTER The Leukemia & Lymphoma Society's CTSC can help physicians provide their patients with assistance finding and enrolling in clinical

trials.

LEARN MORE

NEW ASH CLINICAL PRACTICE GUIDELINES ON SICKLE CELL DISEASE-RELATED

TRANSFUSION SUPPORT

These guidelines are part of a series of five guidelines ASH is developing on SCD to provide updated treatment guidelines that reflect the newest evidence about the disease, ensuring the medical community can better treat SCD and people with SCD can make the best decisions

for their care.

LEARN MORE

MEETINGS

ASH MEETING ON LYMPHOMA BIOLOGY

August 6-9, 2020

Westfields Marriott, Chantilly, VA, (near Washington, DC)

Learn more

ASH Meeting on Hematologic Malignancies Sept. 11-12, 2020 | Chicago, IL

LEARN MORE

ASH Consultative Hematology Course Sept. 10, 2020 | Chicago, IL Dec. 7, 2020 | San Diego, CA

LEARN MORE

UPCOMING DEADLINES

May 1 - ASH Bridge Grant May 1 - ASH Scholar Awards April 30 - ASH Medical Educators Institute

LEARN MORE

-------------------------

RESEARCH

The American Society of Hematology (ASH) leads the world in promoting and supporting clinical and scientific hematology research through its many innovative award programs, meetings, publications, and advocacy

efforts.

ASH Research Programs and Awards Learn More ASH Agenda for Hematology Research Learn More Annual Meeting Abstracts Learn More View More ASH Research -------------------------

EDUCATION

__ Guidelines & Quality Care __ Professional Development __ Educational Programs The American Society of Hematology offers a wide array of educational products and services for clinicians and scientists at any stage in

their careers.

FOR CLINICIANS

ASH is committed to helping practicing hematologists provide quality care to patients, continue their professional development, and enhance their knowledge and expertise. Learn More >

FOR TRAINEES

Whether you are medical student, resident, or fellow, ASH provides many programs and resources to help you advance your career as a hematologist. Learn More >

FOR EDUCATORS

As the world's leading provider of hematology education, ASH offers many programs and resources for educators working in the field of hematology. Learn More >

FOR PATIENTS

ASH has developed the resources to educate about the importance of healthy blood and to raise the awareness of common blood diseases.

Learn More >

View More ASH Education -------------------------

PUBLICATIONS

ASH publications include both clinical and scientific research, and education in the field of hematology. With an impact factor of 16.601 (2018), _Blood_ is the most cited peer-reviewed publication in the field of hematology. It provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. _Blood Advances_ is a semimonthly medical journal published by the American Society of Hematology. It is the first journal to join the _Blood_ family in 70 years and is a peer-reviewed, online only, open access journal. Under the direction of founding editor-in-chief Robert Negrin, MD, Stanford University Medical Center, Stanford, CA, the inaugural issue debuted on November 29, 2016. _The Hematologist: ASH News and Reports_, the American Society of Hematology’s member newsletter, is designed for the broad constituency of ASH, ranging from basic scientists to practicing clinicians, all working toward the ultimate goal of conquering blood

diseases.

_ASH Clinical News_, a monthly news magazine specifically designed to appeal to clinical practitioners in hematology and oncology, provides timely updates in the field by reporting on key medical meetings, clinical trials, innovative technology, and influential papers in the

literature.

View All Publications -------------------------

GET INVOLVED

ASH is always looking for ways to better serve all communities of clinicians and scientists working to conquer blood disease worldwide. Whether you are looking to take action by being an advocate for hematology, support the foundation through donation, or joining a diverse community of more than 17,000 hematologists, you will help conquer blood diseases worldwide. ASH is the leader in representing the interests of scientists and clinicians working in the field of hematology on Capitol Hill and within federal agencies concerned with the study and treatment of blood-related diseases. Learn More Your generosity enables the Foundation to provide critical support to the field of hematology through programs in research, career development, and quality care and education. Learn more about the ASH Foundation. Learn More Whether you are a medical student planning your career in hematology or an established physician or scientist with years of experience in the field, ASH offers benefits and opportunities for hematologists around the globe at every career level. Learn More Learn About ASH Global Initiatives -------------------------

ASH FAMILY OF SITES

ASH Publications

ASH Store

ASH Pocket Guides

ASH Job Center

ASH On Demand

ASH Image Bank

ASH Academy

ASH provides the most current practice tools, clinical support, and educational products in hematology that you need for every stage of your career. Our family of sites, developed by subject-matter experts, are designed to help physicians improve their medical knowledge, engage in quality activities, meet and learn from thousands of hematologists worldwide and continue to help conquer blood diseases

worldwide.

Learn More about ASH American Society of Hematology 2021 L Street NW, Suite 900, Washington, DC 20036

Contact

Phone 202-776-0544

Toll Free 866-828-1231

Fax 202-776-0545

Social

__ __

__

__

Copyright © 2020 by American Society of Hematology Support Opportunities |Privacy Policy

|Terms of Service

|Contact Us

LAST REVISED: MAY 1, 2018 Thank you for your interest in how ASH uses cookies on our Sites. We have provided this Cookie Policy to provide you with transparency so you can make informed choices about how your personal data in the form of your internet protocol address is tracked utilizing cookies by ASH and other third parties. This Cookie Policy explains how your personal data is shared and analyzed by our third-party vendor service providers to improve the performance and user satisfaction of our Sites, to help those Sites function properly for your use and convenience, to enable third-party advertisers to serve you ads, to provide you with other content that is optimized for you based upon your use of the Sites, and your ability to share such content on social media. Identification of Individuals to Contact at ASH regarding questions concerning Cookies We hope that this Cookie Policy helps you understand and provides a good explanation for our use of cookies on the Sites. If after reviewing this policy you have any further questions for us, require assistance or have requests based upon the information provide here, please contact us at customerservice@hematology.org. What are Cookies? Cookies are small physical data files that are automatically placed on to your computer’s browser as you navigate the web. Cookies can provide a great deal of insight into your activity and preferences, and in some cases can be used to identify you. For this reason we want to provide as much information to you about the cookies we use and how we manage cookies when you provide us with your consent. Your consent enables us to use cookies to track your activity across our Sites in order to accomplish the objectives outlined in this Cookie Policy. Visiting our Sites This Cookie Policy shall apply to the ASH domain owned by us any subsite, subdomain, subdirectory, virtual site, or virtual directory thereof (each, a “Site” and collectively the "Sites") For some of our Sites, we may post a Cookie Policy that is Site specific. We do this in order to best describe the use of cookies for Sites that are administered by our third party vendor partners. By posting a separate and site specific policy on these selected Sites, we are able to provide transparency to you and describe in detail where the use of cookies is configured in a way that is different than how ASH typically manages cookies on its Sites or as explained in this Cookie Policy. The reasons for this is that some of our third party site administrators are in the process of developing and upgrading their compliance and technical use capabilities in the interest of providing maximum choice to visitors to the Sites. These Sites include www.bloodjournal.org, www.bloodadvances.org, www.ash-sap.org and www.asheducationbook.hematology.org. For these Sites, we will continue to update you as the technical and compliance capabilities are enhanced and additional choices regarding the use of cookies becomes available to you. Obtaining Your Consent and Your Choices The first time you visit the Sites, you will be provided with a Cookie Disclosure “pop up” window that informs you “ASH uses cookies to personalize content and ads in order to provide social media features and to analyze our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine with other information that you’ve provided to them or that they have collected from your use of their services.” ASH will require you to identify by checking the boxes designed to determine your specific choices regarding the categories of Cookies to be used each time you visit the Sites. By clicking on the “OK” button, you are providing ASH with your consent to utilize the relevant cookies for each of the individual categories chosen by you which are described more fully below in this Cookie Policy. Changing Your Choices Note that each time you return to the site, you have the option of changing your choices by clicking on the Cookie Settings tab and revising your choices if you so desire. If you revise your choices, ASH will clear the cookies in the specific categories you have selected and those cookies will no longer track your activity on the Sites. If you do not ask for your settings to be changed, your previous choices and the previous consent you provided to ASH will apply to your current session on the Sites. Description of the General Categories of Cookies for Selection and Opt In: Necessary: These cookies are essential to the functionality of the Sites in order to facilitate your use of the Sites and its features and in order to enable you to move around the Sites smoothly. Without these cookies, we may not be able to provide certain services or features, and the Sites will not properly function. Unfortunately, these cookies cannot be disabled or modified, which is why we refer to these as necessary. Preferences: In some circumstances, we may use functionality cookies which we describe as “Preferences” cookies. The cookies allow us to remember the choices you make while browsing the Sites, and to provide enhanced and more personalized content and features, such as customizing a certain webpage, remembering if we have asked you to participate in a promotion and for other services you request, like watching a video or commenting on a blog. In order to permit your connection to the Sites, our servers receive and record information about your computer, device, and browser, including your IP address, browser type, and other software or hardware information. If you access the Sites from a mobile or other device, we may collect a unique device identifier assigned to that device ("UDID"), geolocation data, or other transactional information for that device. All of these features help us to improve your visit to the Site. Statistics and Analytics: We and our third-party vendor service providers may use analytics cookies, which are sometimes called performance or analytics cookies, to collect information about your use of the Sites and enable us to improve the way it works and prepare statistical analysis of such analytics. Analytics cookies collect information about how you use the Sites, for instance, which pages you go to most. The information allows us to see the overall patterns of usage on the Sites, help us record any difficulties you have with the Sites, and show us whether our advertising is effective or not. Marketing: We and our third-party vendor partners may use advertising cookies to deliver ads that we believe are more relevant to you and your interests on our Sites and other sites. For example, we may use targeting or advertising cookies to customize the advertising and content you receive on our Sites, to limit the number of times you see the same ad on our Sites, and to help measure the effectiveness of our advertising campaigns. These cookies remember what you have looked at on the Sites and other sites, and may be combined with other information acquired from third parties, and we may share this information with other organizations, such as advertisers, in order the best determine how to drive content to you that you may find useful based upon your browsing experience. Within the category of marketing, we also include social plug-in tracking cookies that can be used to track both members and non-members of social networks for "additional" purposes such as behavioral advertising, analytics, and market research. For more information about targeting and advertising cookies and how you can opt out, visit: Network Advertising Initiative: http://www.networkadvertising.org/choices/ Digital Advertising Alliance: http://www.aboutads.info/choices/ http://www.allaboutcookies.org/manage-cookies/index.html How Do Third Parties Use Cookies on Our Sites in Connection With Our Services? In some circumstances, we may work with third parties to provide services on our Sites. For example, we use analytics services supported by third-party companies who generate analytics cookies on our behalf. We may not have access to these or remove third-party cookies, although we may use statistical information arising from the cookies provided by these third parties to customize content and for the other purposes described above. These companies may also transfer this information to other parties where required to do so by law, or where such other parties process the information on their behalf. Third-party advertisers and other organizations may also use their own cookies to collect information about your activities on our Site and/or the advertisements you have clicked on. This information, which may be combined with other information acquired from third parties, may be used by them to serve advertisements on our Sites and third party sites that they believe are most likely to be of interest to you based on content you have viewed. Third-party advertisers may also use this information to measure the effectiveness of their advertisements and to track aggregate usage statistics. We may not control these third-party cookies and their use may be governed by the privacy policies of the third parties employing these cookies. How Does My Opting Out of or Not Consenting to Cookies Work If There Are Third-Party Cookies You Cannot Access or Control? The cookie is a physical data file script that is set into the browser which captures the data in accordance with the instructions coded into the script which is set by the third parties. When you make your choices regarding our use of cookies, our third-party software service provider, CookieBot, ensures the specific scripts associated with these third party cookies are removed so that scripts corresponding to those cookies and providing instructions regarding data capture are disabled. Although the cookie is not specifically removed unless you clear your browser or take other action to block these cookies as described below, the tracking functionality is stopped by CookieBot’s software. How Can You Further Control Cookies on the Sites? You may outright refuse to accept cookies from the Sites at any time by activating the setting on your browser which allows you to refuse cookies. Further information about the procedure to follow in order to disable cookies can be found on your Internet browser provider’s website via your help screen. You may wish to refer to http://www.allaboutcookies.org/manage-cookies/index.html for information on commonly used browsers. Please note that by disabling or blocking any or all cookies, some features of the Sites may not operate as intended, or you may not have access to features or personalization available through the Site. Analytics cookies can also be managed via the following link: Google Analytics: http://tools.google.com/dlpage/gaoptout. How does ASH respond to Do Not Track signals? ASH utilizes a third-party software service provider, CookieBot, to manage consents for cookies utilized by the Sites. If you have enabled the your web browser’s DO NOT TRACK (DNT) settings Cookiebot will not set the third party cookie CookieConsentBulkTicket used for bulk consent. Changes and Revisions to This Cookie Policy Please take a look at the Last Revised date at the top of this page to see when this Cookie Policy was last revised. Any changes in this Cookie Policy will become effective when we make the revised Cookie Policy available on or through the Site. How Do Third Parties Use Cookies on Our Sites in Connection With Our Services? In some circumstances, we may work with third parties to provide services on our Sites. For example, we use analytics services supported by third-party companies who generate analytics cookies on our behalf. We may not have access to these or remove third-party cookies, although we may use statistical information arising from the cookies provided by these third parties to customize content and for the other purposes described above. These companies may also transfer this information to other parties where required to do so by law, or where such other parties process the information on their behalf. Third-party advertisers and other organizations may also use their own cookies to collect information about your activities on our Site and/or the advertisements you have clicked on. This information, which may be combined with other information acquired from third parties, may be used by them to serve advertisements on our Sites and third party sites that they believe are most likely to be of interest to you based on content you have viewed. Third-party advertisers may also use this information to measure the effectiveness of their advertisements and to track aggregate usage statistics. We may not control these third-party cookies and their use may be governed by the privacy policies of the third parties employing these cookies. How Does My Opting Out of or Not Consenting to Cookies Work If There Are Third-Party Cookies You Cannot Access or Control? The cookie is a physical data file script that is set into the browser which captures the data in accordance with the instructions coded into the script which is set by the third parties. When you make your choices regarding our use of cookies, our third-party software service provider, CookieBot, ensures the specific scripts associated with these third party cookies are removed so that scripts corresponding to those cookies and providing instructions regarding data capture are disabled. Although the cookie is not specifically removed unless you clear your browser or take other action to block these cookies as described below, the tracking functionality is stopped by CookieBot’s software. How Can You Further Control Cookies on the Sites? You may outright refuse to accept cookies from the Sites at any time by activating the setting on your browser which allows you to refuse cookies. Further information about the procedure to follow in order to disable cookies can be found on your Internet browser provider’s website via your help screen. You may wish to refer to http://www.allaboutcookies.org/manage-cookies/index.html for information on commonly used browsers. Please note that by disabling or blocking any or all cookies, some features of the Sites may not operate as intended, or you may not have access to features or personalization available through the Site. Analytics cookies can also be managed via the following link: Google Analytics: http://tools.google.com/dlpage/gaoptout. How does ASH respond to Do Not Track signals? ASH utilizes a third-party software service provider, CookieBot, to manage consents for cookies utilized by the Sites. If you have enabled the your web browser’s DO NOT TRACK (DNT) settings Cookiebot will not set the third party cookie CookieConsentBulkTicket used for bulk consent. Changes and Revisions to This Cookie Policy Please take a look at the Last Revised date at the top of this page to see when this Cookie Policy was last revised. Any changes in this Cookie Policy will become effective when we make the revised Cookie Policy available on or through the Site. Your consent applies to the following domains: www.hematology.org, hematology.org, testing.hematology.org, eus-prd-1045176-xp3-cd.azurewebsites.net Your current state: Use necessary cookies only. Your current state: Do Not Sell My Personal Information. Your current state: Allow all cookies (Necessary, Preferences, Statistics, Marketing). Your consent ID: Consent date: Your current state: Allow all cookies. Change your consent  |  Withdraw your consent Do Not Sell My Personal Information Cookie declaration last updated on 05/03/2020 by Cookiebot

:

Necessary (25)

Necessary: These cookies are essential to the functionality of the Sites in order to facilitate your use of the Sites and its features and in order to enable you to move around the Sites smoothly. Without these cookies, we may not be able to provide certain services or features, and the Sites will not properly function. Unfortunately, these cookies cannot be disabled or modified, which is why we refer to

these as necessary.

NAME

PROVIDER

PURPOSE

EXPIRY

TYPE

__RequestVerificationToken American Society of Hematology Helps prevent Cross-Site Request Forgery (CSRF) attacks.

Session

HTTP Cookie

Acceptance

American Society of Hematology

Pending

1 year

HTTP Cookie

ARRAffinity

American Society of Hematology

Microsoft

Used to distribute traffic to the website on several servers in order to optimise response times.

Session

HTTP Cookie

ASP.NET_SessionId

American Society of Hematology Preserves the visitor's session state across page requests.

Session

HTTP Cookie

AWSELB

Crazyegg

Used to distribute traffic to the website on several servers in order to optimise response times.

Session

HTTP Cookie

ce_diff_time

www.fda.gov

Pending

Session

HTML Local Storage

ce_ip_address

www.fda.gov

Pending

Session

HTML Local Storage

CookieConsent

Cookiebot

Stores the user's cookie consent state for the current domain

1 year

HTTP Cookie

ecm

American Society of Hematology

Pending

Session

HTTP Cookie

JSESSIONID

New Relic

American Society of Hematology Preserves users states across page requests.

Session

HTTP Cookie

localization

Flickr

Registers the user's geographical location in order to show content from the server located closest to the user.

2 years

HTTP Cookie

OpenIdConnect.nonce.# American Society of Hematology

Pending

1 day

HTTP Cookie

QSI_History

www.fda.gov

Pending

Session

HTML Local Storage

rc::c

Google

This cookie is used to distinguish between humans and bots.

Session

HTML Local Storage

s_ptc

Flickr

Registers the website's speed and performance. This function can be used in context with statistics and load-balancing.

Session

HTTP Cookie

Preferences (24)

Preferences: In some circumstances, we may use functionality cookies which we describe as “Preferences” cookies. The cookies allow us to remember the choices you make while browsing the Sites, and to provide enhanced and more personalized content and features, such as customizing a certain webpage, remembering if we have asked you to participate in a promotion and for other services you request, like watching a video or commenting on a blog. In order to permit your connection to the Sites, our servers receive and record information about your computer, device, and browser, including your IP address, browser type, and other software or hardware information. If you access the Sites from a mobile or other device, we may collect a unique device identifier assigned to that device ("UDID"), geolocation data, or other transactional information for that device. All of these features help us to improve your visit to the Site.

NAME

PROVIDER

PURPOSE

EXPIRY

TYPE

addevent_track_cookie American Society of Hematology If consent is given by the visitor, this cookie allows the website to add events into the visitor's calendar.

1 year

HTTP Cookie

com.adobe.reactor.dataElementCookiesMigrated

Flickr

Pending

Persistent

HTML Local Storage

com.adobe.reactor.dataElements.User Class

Flickr

Pending

Persistent

HTML Local Storage

com.adobe.reactor.dataElements.User ID

Flickr

Pending

Persistent

HTML Local Storage

com.adobe.reactor.dataElements.User Intl

Flickr

Pending

Persistent

HTML Local Storage

com.adobe.reactor.dataElements.User Language

Flickr

Pending

Persistent

HTML Local Storage

CookieConsentBulkSetting-#

Cookiebot

Enables cookie consent across multiple websites

Persistent

HTML Local Storage

flrb

Flickr

Pending

1 day

HTTP Cookie

flrbgdrp

Flickr

Pending

180 days

HTTP Cookie

flrbgmrp

Flickr

Pending

180 days

HTTP Cookie

flrbgrp

Flickr

Pending

180 days

HTTP Cookie

flrbp

Flickr

Pending

180 days

HTTP Cookie

flrbrgs

Flickr

Pending

180 days

HTTP Cookie

flrbrp

Flickr

Pending

180 days

HTTP Cookie

flrbrst

Flickr

Pending

180 days

HTTP Cookie

flrbs

Flickr

Pending

180 days

HTTP Cookie

flrtags

Flickr

Pending

180 days

HTTP Cookie

hematology#lang

American Society of Hematology

Microsoft

Pending

Session

HTTP Cookie

jwplayerLocalId

JW Player

Used to determine the optimal video quality based on the visitor's device and network settings.

Persistent

HTML Local Storage

QSI_HistorySession

fda.gov

Pending

Session

HTTP Cookie

s_pec

Flickr

Pending

Session

HTML Local Storage

xb

Flickr

Pending

10 years

HTTP Cookie

Statistics (25)

Statistics and Analytics: We and our third-party vendor service providers may use statistics cookies, which are sometimes called performance or analytics cookies, to collect information about your use of the Sites and enable us to improve the way it works and prepare statistical analysis of such analytics. Analytics cookies collect information about how you use the Sites, for instance, which pages you go to most. The information allows us to see the overall patterns of usage on the Sites, help us record any difficulties you have with the Sites, and show us whether our advertising is effective or not.

NAME

PROVIDER

PURPOSE

EXPIRY

TYPE

_at.hist.#

American Society of Hematology

Microsoft

Used by the social sharing platform AddThis to store the user's usage history of the AddThis sharing widget

Persistent

HTML Local Storage

_ga

fda.gov

Google Tag Manager

Registers a unique ID that is used to generate statistical data on how the visitor uses the website.

2 years

HTTP Cookie

_gat

fda.gov

Google Tag Manager

Used by Google Analytics to throttle request rate

1 day

HTTP Cookie

_gid

fda.gov

Google Tag Manager

Registers a unique ID that is used to generate statistical data on how the visitor uses the website.

1 day

HTTP Cookie

AMCV_#

Flickr

Unique user ID that recognizes the user on returning visits

2 years

HTTP Cookie

AMCVS_#AdobeOrg

Flickr

Pending

Session

HTTP Cookie

AWSELBCORS

Crazyegg

Pending

Session

HTTP Cookie

collect

Google

Used to send data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing

channels.

Session

Pixel Tracker

EkAnalytics

American Society of Hematology

Pending

1 year

HTTP Cookie

events/1/#

New Relic

Pending

Session

Pixel Tracker

personalization_id

Twitter

This cookie is set by Twitter - The cookie allows the visitor to share content from the website onto their Twitter profile.

2 years

HTTP Cookie

s_cc

Flickr

Used to check if the user's browser supports cookies.

Session

HTTP Cookie

s_ppv

Flickr

Saves information on what vertical percentage of a page has been displayed to the user.

Session

HTTP Cookie

sc_anonymous_id

Soundcloud

This cookie allows users to embed files or other content onto the website, this function can be limited to specific visitors.

10 years

HTTP Cookie

TEST_AMCV_COOKIE

Flickr

Registers statistical data on visitors' behaviour on the website. Used for internal analytics by the website operator.

2 years

HTTP Cookie

Marketing (42)

Marketing: We and our third-party vendor partners may use advertising cookies to deliver ads that we believe are more relevant to you and your interests on our Sites and other sites. For example, we may use targeting or advertising cookies to customize the advertising and content you receive on our Sites, to limit the number of times you see the same ad on our Sites, and to help measure the effectiveness of our advertising campaigns. These cookies remember what you have looked at on the Sites and other sites, and may be combined with other information acquired from third parties, and we may share this information with other organizations, such as advertisers, in order the best determine how to drive content to you that you may find useful based upon your browsing experience. Within the category of marketing, we also include social plug-in tracking cookies that can be used to track both members and non-members of social networks for "additional" purposes such as behavioral advertising, analytics, and market research. For more information about targeting and advertising cookies and how you can opt out, visit: Network Advertising Initiative: http://www.networkadvertising.org/choices/ Digital Advertising Alliance: http://www.aboutads.info/choices/ http://www.allaboutcookies.org/manage-cookies/index.html

NAME

PROVIDER

PURPOSE

EXPIRY

TYPE

__atuvc

Oracle

Updates the counter of a website's social sharing features.

13 months

HTTP Cookie

__atuvs

Oracle

Ensures that the updated counter is displayed to the user if a page is shared with the social sharing service, AddThis.

1 day

HTTP Cookie

__gads

American Society of Hematology Used to register what ads have been displayed to the user.

2 years

HTTP Cookie

_at.cww

American Society of Hematology

Microsoft

Used by the social sharing platform AddThis

Persistent

HTML Local Storage

_fbp

American Society of Hematology Used by Facebook to deliver a series of advertisement products such as real time bidding from third party advertisers.

3 months

HTTP Cookie

ads/ga-audiences

Google

Used by Google AdWords to re-engage visitors that are likely to convert to customers based on the visitor's online behaviour across

websites.

Session

Pixel Tracker

at-lojson-cache-#

American Society of Hematology

Microsoft

Used by the social sharing platform AddThis

Persistent

HTML Local Storage

at-rand

American Society of Hematology

Microsoft

Used by the social sharing platform AddThis

Persistent

HTML Local Storage

consent/hod

Adroll

Registers data on visitors from multiple visits and on multiple websites. This information is used to measure the efficiency of advertisement on websites.

Session

Pixel Tracker

demdex

Adobe Inc

Via a unique ID that is used for semantic content analysis, the user's navigation on the website is registered and linked to offline data from surveys and similar registrations to display targeted ads.

179 days

HTTP Cookie

EktGUID

American Society of Hematology This cookie is used to collect information on a visitor. This information will become an ID string with information on a specific visitor – ID information strings can be used to target groups with similar preferences, or can be used by third-party domains or

ad-exchanges.

1 year

HTTP Cookie

fr

Facebook

Used by Facebook to deliver a series of advertisement products such as real time bidding from third party advertisers.

3 months

HTTP Cookie

google_experiment_mod# American Society of Hematology Used by Google AdSense for experimenting with advertisement efficiency across websites using their services.

Persistent

HTML Local Storage

GoogleAdServingTest

American Society of Hematology Used to register what ads have been displayed to the user.

Session

HTTP Cookie

GPS

YouTube

Registers a unique ID on mobile devices to enable tracking based on geographical GPS location.

1 day

HTTP Cookie

IDE

Google

Used by Google DoubleClick to register and report the website user's actions after viewing or clicking one of the advertiser's ads with the purpose of measuring the efficacy of an ad and to present targeted ads to the user.

1 year

HTTP Cookie

loc

Oracle

Geolocation, which is used to help providers determine how users who share information with each other are geographically located

(state level).

13 months

HTTP Cookie

r/collect

Google

This cookie is used to send data to Google Analytics about the visitor's device and behavior. It tracks the visitor across devices and marketing channels.

Session

Pixel Tracker

test_cookie

Google

Used to check if the user's browser supports cookies.

1 day

HTTP Cookie

uvc

Oracle

Detects how often the social sharing service, AddThis, encounters

the same user.

13 months

HTTP Cookie

VISITOR_INFO1_LIVE

YouTube

Tries to estimate the users' bandwidth on pages with integrated

YouTube videos.

180 days

HTTP Cookie

WIDGET::local::assignments

Soundcloud

Used by audio-platform SoundCloud to implement, measure and improve their embedded content/service on the website - The collection of data also includes visitors’ interaction with embedded content/service. This can be used for statistics or marketing purposes.

Persistent

HTML Local Storage

xtc

Oracle

Registers the user's sharing of content via social media.

13 months

HTTP Cookie

YSC

YouTube

Registers a unique ID to keep statistics of what videos from YouTube the user has seen.

Session

HTTP Cookie

yt-remote-cast-installed

YouTube

Stores the user's video player preferences using embedded YouTube

video

Session

HTML Local Storage

yt-remote-connected-devices

YouTube

Stores the user's video player preferences using embedded YouTube

video

Persistent

HTML Local Storage

yt-remote-device-id

YouTube

Stores the user's video player preferences using embedded YouTube

video

Persistent

HTML Local Storage

yt-remote-fast-check-period

YouTube

Stores the user's video player preferences using embedded YouTube

video

Session

HTML Local Storage

yt-remote-session-app

YouTube

Stores the user's video player preferences using embedded YouTube

video

Session

HTML Local Storage

yt-remote-session-name

YouTube

Stores the user's video player preferences using embedded YouTube

video

Session

HTML Local Storage

Unclassified (6)

Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.

NAME

PROVIDER

PURPOSE

EXPIRY

TYPE

aws.cognito.identity-id.us-east-1:28f470c9-1c97-406f-bc8b-c4de10ef5fe3

Amazon

Pending

Persistent

HTML Local Storage

b1Pi

American Society of Hematology

Pending

Session

HTTP Cookie

DT

American Society of Hematology

Pending

2 years

HTTP Cookie

oktaStateToken

American Society of Hematology

Pending

1 day

HTTP Cookie

s_tp

Flickr

Pending

Session

HTTP Cookie

t

American Society of Hematology

Pending

Session

HTTP Cookie